263 related articles for article (PubMed ID: 30449032)
1. Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.
Chappell JC; Turner PK; Pak YA; Bacon J; Chiang AY; Royalty J; Hall SD; Kulanthaivel P; Bonventre JV
Clin Pharmacol Ther; 2019 May; 105(5):1187-1195. PubMed ID: 30449032
[TBL] [Abstract][Full Text] [Related]
2. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
3. Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report.
Maeda A; Irie K; Hashimoto N; Fukushima S; Ando H; Okada A; Ebi H; Kajita M; Iwata H; Sawaki M
Invest New Drugs; 2021 Feb; 39(1):272-277. PubMed ID: 32856274
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy Increases the Renal Secretion of N
Bergagnini-Kolev MC; Hebert MF; Easterling TR; Lin YS
Drug Metab Dispos; 2017 Mar; 45(3):325-329. PubMed ID: 28069720
[TBL] [Abstract][Full Text] [Related]
5. Significance of Organic Anion Transporter 2 and Organic Cation Transporter 2 in Creatinine Clearance: Mechanistic Evaluation Using Freshly Prepared Human Primary Renal Proximal Tubule Cells.
Mathialagan S; Chung G; Pye K; Rodrigues AD; Varma MVS; Brown C
J Pharmacol Exp Ther; 2024 Jan; 388(1):201-208. PubMed ID: 37977812
[TBL] [Abstract][Full Text] [Related]
6. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
Xiao G; Rowbottom C; Boiselle C; Gan LS
Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
[TBL] [Abstract][Full Text] [Related]
7. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
[TBL] [Abstract][Full Text] [Related]
8. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat.
Lepist EI; Zhang X; Hao J; Huang J; Kosaka A; Birkus G; Murray BP; Bannister R; Cihlar T; Huang Y; Ray AS
Kidney Int; 2014 Aug; 86(2):350-7. PubMed ID: 24646860
[TBL] [Abstract][Full Text] [Related]
10. The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.
Iriyama N; Hino H; Moriya S; Hiramoto M; Hatta Y; Takei M; Miyazawa K
Leuk Lymphoma; 2018 Jun; 59(6):1439-1450. PubMed ID: 28918692
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
12. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine.
Mathialagan S; Rodrigues AD; Feng B
J Pharm Sci; 2017 Sep; 106(9):2535-2541. PubMed ID: 28416419
[TBL] [Abstract][Full Text] [Related]
14. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
15. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells.
Tsuda M; Terada T; Ueba M; Sato T; Masuda S; Katsura T; Inui K
J Pharmacol Exp Ther; 2009 Apr; 329(1):185-91. PubMed ID: 19164462
[TBL] [Abstract][Full Text] [Related]
16. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
17. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of atenolol on urinary excretion of metformin via down-regulating multidrug and toxin extrusion protein 1 (rMate1) expression in the kidney of rats.
Ma YR; Huang J; Shao YY; Ma K; Zhang GQ; Zhou Y; Zhi R; Qin HY; Wu XA
Eur J Pharm Sci; 2015 Feb; 68():18-26. PubMed ID: 25486332
[TBL] [Abstract][Full Text] [Related]
19. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.
Groenland SL; Martínez-Chávez A; van Dongen MGJ; Beijnen JH; Schinkel AH; Huitema ADR; Steeghs N
Clin Pharmacokinet; 2020 Dec; 59(12):1501-1520. PubMed ID: 33029704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
